within Pharmacolibrary.Drugs.ATC.P;

model P02DA01
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.1,
    Cl             = 3.533333333333333e-05,
    adminDuration  = 600,
    adminMass      = 2000 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.00016,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.001,
    Tlag           = 600
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>P02DA01</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Niclosamide is an anthelmintic drug primarily used to treat tapeworm infections in humans, approved for use in many countries since the 1960s. It is listed on the WHO Model List of Essential Medicines. Recently, it has gained renewed interest for repurposing against other conditions, including viral infections and cancer.</p><h4>Pharmacokinetics</h4><p>Single oral administration in healthy adult volunteers; pharmacokinetics reported after 2 g oral dose.</p><h4>References</h4><ol><li><p>Bhanushali, JS, et al., &amp; Bharate, SS (2022). Molecular interactions of niclosamide with hydroxyethyl cellulose in binary and ternary amorphous solid dispersions for synergistic enhancement of water solubility and oral pharmacokinetics in rats. <i>International journal of pharmaceutics</i> 626 122144–None. DOI:<a href=&quot;https://doi.org/10.1016/j.ijpharm.2022.122144&quot;>10.1016/j.ijpharm.2022.122144</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/36029996/&quot;>https://pubmed.ncbi.nlm.nih.gov/36029996</a></p></li><li><p>Weiss, A, et al., &amp; Sommer, MO (2023). Single-dose pharmacokinetics and lung function of nebulized niclosamide ethanolamine in sheep. <i>Pharmaceutical research</i> 40(8) 1915–1925. DOI:<a href=&quot;https://doi.org/10.1007/s11095-023-03559-0&quot;>10.1007/s11095-023-03559-0</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/37498498/&quot;>https://pubmed.ncbi.nlm.nih.gov/37498498</a></p></li><li><p>Walther, N, et al., &amp; Posch, MG (2025). Clinical safety and pharmacokinetics of a novel oral niclosamide formulation compared with marketed niclosamide chewing tablets in healthy volunteers: A three-part randomized, double-blind, placebo-controlled trial. <i>PloS one</i> 20(2) e0303924–None. DOI:<a href=&quot;https://doi.org/10.1371/journal.pone.0303924&quot;>10.1371/journal.pone.0303924</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/39999124/&quot;>https://pubmed.ncbi.nlm.nih.gov/39999124</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end P02DA01;
